Oxytocin
Oxytocin is a neuropeptide hormone produced in the hypothalamus known as "the love hormone." It plays a key role in emotional bonding, social connection, anxiety relief, and intimacy support. FDA-approved for obstetric use (Pitocin), it is used off-label in peptide therapy for mood, social bonding, and sexual health. Neuropeptide hormone secreted by the posterior pituitary. Promotes bedtime bonding and emotional security. Activates calm-rest-digest (parasympathetic) circuitry and social safety signals. Reduces amygdala response, modulating fear and anxiety. Increases emotional connection and physical response. Reduces the need for artificial stimulation. - Social bonding and trust building - Anxiety reduction and emotional regulation
This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.
Research summary
| Study | Type | Year | Key Finding |
|---|---|---|---|
| Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. | Meta-analysis of randomized controlled trials (random-effects model with meta-regression) | 2018 | Pooled 17 randomized controlled trials comprising 466 participants with neurodevelopmental disorders, searched through 25 July 2017 |
| Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. | Systematic review and meta-analysis of randomized controlled trials — safety and adverse event profile | 2018 | Pooled 5 randomized controlled trials with 223 participants (123 oxytocin, 100 placebo) published before 1 January 2017 |
| Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials. | Systematic review, random-effects meta-analysis, and dose-response meta-analysis of randomized controlled trials | 2021 | In the initial analysis of all 9 identified randomized clinical trials, intranasal oxytocin showed no significant effect on negative symptoms of schizophrenia |
| Intranasal Oxytocin for Obesity. | Randomized, double-blind, placebo-controlled trial (NCT03043053) — negative result on the primary endpoint | 2024 | NEGATIVE PRIMARY ENDPOINT: intranasal oxytocin 24 IU four times daily for 8 weeks did not reduce body weight versus placebo (0.20 vs. 0.26 kg change; P=0.934) |
Stacks containing Oxytocin
28-day resets featuring Oxytocin
Sourcing
Current prices
2mg
Only vendor stocking this size on the VialBase roster.
- Ascension Peptides$49.99Buy at Ascension Peptides → Save 50% via this link
10mg
- Verified Peptides$35.00 best
- Certified-Pep$52.00
- Core Peptides$52.00
- BioLongevity Labs$64.97Buy at BioLongevity Labs → Save 15% with code
VIALBASE - Licensed Peptides$191.70
Size unspecified
Only vendor stocking this size on the VialBase roster.
- Swiss Chems$21.95Buy at Swiss Chems → Save 10% with code
aewpzbzd
Save 15% with code
VIALBASE at checkout
Save 10% with code
aewpzbzd at checkout
VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.
- Ascension Peptides Third-party tested Public COAs
- Core Peptides Third-party tested Public COAs
- Licensed Peptides Third-party tested Public COAs
- Verified Peptides Third-party tested Public COAs
What bloodwork do I need?
Reference ranges are general guidelines. Consult your physician for interpretation.
- CMP
- CBC
- Blood Pressure
- Blood Pressure
- CMP
Safety & Regulatory Status
Regulatory status for Oxytocin may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.
Frequently Asked Questions
References
- Keech B, Crowe S, Hocking DR. Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis.. Psychoneuroendocrinology (2018). PMID: 29032324
- Cai Q, Feng L, Yap KZ. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.. Psychiatry and clinical neurosciences (2018). PMID: 29232031
- Sabe M, Zhao N, Crippa A, et al.. Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials.. The international journal of neuropsychopharmacology (2021). PMID: 33890987
- Plessow F, Kerem L, Wronski ML, et al.. Intranasal Oxytocin for Obesity.. NEJM evidence (2024). PMID: 38815173